SP100030 is a novel T-cell-specific transcription factor inhibitor that possesses immunosuppressive activity in vivo.
Goldman
M E
ME
Department of Pharmacology, Signal Pharmaceuticals, Inc, San Diego, California 92121, USA. mgoldman@signalpharm.com
Ransone
L J
LJ
Anderson
D W
DW
Gaarde
W A
WA
Suto
M J
MJ
Sullivan
R W
RW
Shorthouse
R
R
Morikawa
M
M
Morris
R E
RE
D000818:Animals; D001169:Arthritis, Experimental / Q000276:immunology* / Q000517:prevention & control; D001835:Body Weight / Q000187:drug effects; D003907:Dexamethasone / Q000494:pharmacology; D005260:Female; D016027:Heart Transplantation / Q000276:immunology*; D006965:Hyperplasia; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007519:Isoantigens / Q000276:immunology; D008198:Lymph Nodes / Q000276:immunology* / Q000473:pathology; D017710:Lymphocyte Transfusion; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000528:radiation effects; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D009930:Organic Chemicals; D051381:Rats; D011917:Rats, Inbred Lew; D013154:Spleen; D016042:Transplantation, Heterotopic; D000813:Anilides; D001549:Benzamides; D011743:Pyrimidines
D003907:Dexamethasone; D007166:Immunosuppressive Agents; D007519:Isoantigens; D009930:Organic Chemicals; C102914:N-(3,5-bis(trifluoromethyl)phenyl)-2-chloro-4-(trifluoromethyl)pyrimidine-5-carboxamide; D000813:Anilides; D001549:Benzamides; D011743:Pyrimidines